Windtree Therapeutics Inc
NASDAQ:WINT
Windtree Therapeutics Inc
NASDAQ:WINT
Price:
4.94 USD
14.09%
Market Closed
Updated:
May 6, 2024
Windtree Therapeutics Inc
Net Income (Common)
|
Windtree Therapeutics Inc
Net Income (Common) Peer Comparison
Comparables:
ABBV
GILD
AMGN
VRTX
REGN
Competitive Net Income (Common) Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Net Income (Common) | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
Windtree Therapeutics Inc
NASDAQ:WINT
|
Net Income (Common)
-$20.3m
|
CAGR 3-Years
15%
|
CAGR 5-Years
10%
|
CAGR 10-Years
8%
|
|
|
Abbvie Inc
NYSE:ABBV
|
Net Income (Common)
$4.8B
|
CAGR 3-Years
2%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
2%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Net Income (Common)
$484m
|
CAGR 3-Years
17%
|
CAGR 5-Years
-39%
|
CAGR 10-Years
-20%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Net Income (Common)
$6.7B
|
CAGR 3-Years
-3%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
3%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Net Income (Common)
$3.6B
|
CAGR 3-Years
10%
|
CAGR 5-Years
12%
|
CAGR 10-Years
N/A
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Net Income (Common)
$4B
|
CAGR 3-Years
4%
|
CAGR 5-Years
10%
|
CAGR 10-Years
25%
|
See Also
What is Windtree Therapeutics Inc's Net Income (Common)?
Net Income (Common)
-20.3m
USD
-20.3m
USD
Based on the financial report for Dec 31, 2023, Windtree Therapeutics Inc's Net Income (Common) amounts to -20.3m USD.
What is Windtree Therapeutics Inc's Net Income (Common) growth rate?
Net Income (Common) CAGR 10Y
8%
8%
Over the last year, the Net Income (Common) growth was 48%. The average annual Net Income (Common) growth rates for Windtree Therapeutics Inc have been 15% over the past three years , 10% over the past five years , and 8% over the past ten years .
You don't have any saved screeners yet
